MedTrace Logo

A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

NCT07636772 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2026-06-09

No results posted yet for this study

Summary

This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.

Conditions

  • Urothelial Carcinoma (UC)

Interventions

DRUG

AK146D1 for injection

AK146D1 for injection is an antiTrop2/Nectin4 bispecific antibody-drug conjugate

DRUG

AK112 Injection

AK112 Injection is a PD-1/VEGF bispecific antibody

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2028-08-24
Completion
2028-08-24

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07636772 on ClinicalTrials.gov